Table 3.
Treatment-emergent adverse events for all patients treated with glasdegib.
| Toxicity | Grades 1–2, no. (%) | Grades 3–5, no. (%) | Total, no. (%) |
|---|---|---|---|
| Pain | 22 (63) | 1 (3) | 23 (66) |
| Dysgeusia | 21 (60) | 21 (60) | |
| Nausea | 11 (31) | 11 (31) | |
| Anorexia | 11 (31) | 11 (31) | |
| Skin/rash | 8 (23) | 1 (3) | 9 (26) |
| Oral mucositis | 9 (26) | 9 (26) | |
| AST elevated | 8 (23) | 8 (23) | |
| Alopecia | 8 (23) | 8 (23) | |
| ALT elevated | 6 (17) | 6 (17) | |
| Dizziness | 6 (17) | 6 (17) | |
| Dyspnea | 5 (14) | 1 (3) | 6 (17) |
| Infections | 2 (6) | 4 (11) | 6 (17) |
| Fatigue | 6 (17) | 6 (17) | |
| Diarrhea | 6 (17) | 6 (17) | |
| Constipation | 5 (14) | 5 (14) | |
| Fever | 5 (14) | 5 (14) | |
| Hyperkalemia | 5 (14) | 5 (14) | |
| Hyperglycemia | 4 (11) | 4 (11) | |
| Thrombocytopenia | 2 (6) | 2 (6) | 4 (11) |
| Headache | 4 (11) | 4 (11) |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.